Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial

Fisher BA., Veenith T., Slade D., Gaskell C., Rowland M., Whitehouse T., Scriven J., Parekh D., Balasubramaniam MS., Cooke G., Morley N., Gabriel Z., Wise MP., Porter J., McShane H., Ho L-P., Newsome PN., Rowe A., Sharpe R., Thickett DR., Bion J., Gates S., Richards D., Kearns P., Williams B., Turner R., Libri V., Mussai F., Middleton G., Bowden S., Bangash M., Gao-Smith F., Patel J., Sapey E., Thomas M., Coles M., Watkinson P., Rahman N., Angus B., Mentzer AJ., Novak A., Feldman M., Richter A., Faustini S., Bathurst C., Van de Wiel J., Mee S., James K., Rahman B., Turner K., Hill A., Gordon A., Yap C., Matthay M., McAuley D., Hall A., Dark P., McMichael A.

DOI

10.1016/s2213-2600(21)00460-4

Type

Journal article

Journal

The Lancet Respiratory Medicine

Publisher

Elsevier BV

Publication Date

03/2022

Volume

10

Pages

255 - 266

Permalink Original publication